within Pharmacolibrary.Drugs.ATC.C;

model C09BA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cilazapril is an angiotensin-converting enzyme (ACE) inhibitor, used primarily for the treatment of hypertension and heart failure. It is often combined with thiazide diuretics to enhance antihypertensive effects. The combination is approved for use in many countries for patients who require both an ACE inhibitor and a diuretic for adequate blood pressure control.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic study reporting model parameters for the fixed-dose combination 'cilazapril and diuretics' (ATC C09BA08) was found in the literature. Population pharmacokinetic estimates are made based on published data for cilazapril (as the active cilazaprilat) and hydrochlorothiazide when given separately. Typical adult, oral administration assumed.</p><h4>References</h4><ol><li><p>Krum, H, et al., &amp; Louis, WJ (1992). Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. <i>Journal of cardiovascular pharmacology</i> 20(3) 451–457. DOI:<a href=&quot;https://doi.org/10.1097/00005344-199209000-00017&quot;>10.1097/00005344-199209000-00017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1279292/&quot;>https://pubmed.ncbi.nlm.nih.gov/1279292</a></p></li><li><p>Natoff, IL, et al., &amp; Worth, E (1985). Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. <i>Journal of cardiovascular pharmacology</i> 7(3) 569–580. DOI:<a href=&quot;https://doi.org/10.1097/00005344-198505000-00025&quot;>10.1097/00005344-198505000-00025</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2410692/&quot;>https://pubmed.ncbi.nlm.nih.gov/2410692</a></p></li><li><p>Belz, GG, et al., &amp; Erb, K (1994). Review of studies on the clinical pharmacodynamics of cilazapril. <i>Journal of cardiovascular pharmacology</i> 24 Suppl 2 S14–S19. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7898090/&quot;>https://pubmed.ncbi.nlm.nih.gov/7898090</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09BA08;
